Dyadic International Inc.
1.56
-0.09 (-5.45%)
At close: Jan 14, 2025, 3:59 PM
1.57
0.32%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 1.32
Market Cap 46.31M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.23
PE Ratio (ttm) -6.8
Forward PE n/a
Analyst Buy
Ask 2.5
Volume 82,680
Avg. Volume (20D) 95,344
Open 1.63
Previous Close 1.65
Day's Range 1.52 - 1.67
52-Week Range 0.93 - 2.67
Beta undefined

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific anti...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 16, 2008
Employees 7
Stock Exchange NASDAQ
Ticker Symbol DYAI

Analyst Forecast

According to 1 analyst ratings, the average rating for DYAI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 283.39% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Dyadic International Inc. is scheduled to release its earnings on Mar 27, 2025, during market hours.
Analysts project revenue of $1.35M, reflecting a 96.64% YoY growth and earnings per share of -0.06, making a -25.00% decrease YoY.